<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04670276</url>
  </required_header>
  <id_info>
    <org_study_id>3127 prot.num 0043082/20</org_study_id>
    <nct_id>NCT04670276</nct_id>
  </id_info>
  <brief_title>Conservative Treatment of Gastrointestinal Fistulas by Endoscopic Injection of tSVFem</brief_title>
  <acronym>tSVFem</acronym>
  <official_title>Conservative Treatment of Gastrointestinal Fistulas by Endoscopic Injection of Emulsified Adipose Tissue Stromal Vascular Fraction (tSVFem)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastrointestinal (GI) fistula is a complex condition with high mortality and requiring a&#xD;
      multidisciplinary management.&#xD;
&#xD;
      The aim of this study is to exploit the regenerative-tissue capacities of autologous&#xD;
      emulsified adipose tissue-derived stromal vascular fraction (tSVFem, widely used in other&#xD;
      medical fields - like plastic surgery -for different purposes) harvested and delivered&#xD;
      locally by endoscopy to close the GI fistula.&#xD;
&#xD;
      The proposed technique for the treatment of GI fistulas with tSVFem requires a minimal,&#xD;
      inexpensive, easily reproducible mechanical manipulation of autologous adipose tissue without&#xD;
      necessity of any enzymatic digestion or cell expansion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastrointestinal fistula may be a life-threatening condition caused by several types of&#xD;
      injuries (iatrogenic, traumatic, post-operative), requiring complex and multidisciplinary&#xD;
      management. To date, no clear guidelines have been drawn up for the treatment, that may&#xD;
      include a conservative, minimally invasive, or major surgical approach depending on the&#xD;
      patient's specific clinical characteristics. Furthermore, patients with fistulas are often&#xD;
      fragile, and surgical treatments are highly risky and invasive. Less invasive treatments such&#xD;
      as stenting, endoluminal endoscopic vacuum therapy and suturing are widely employed, but&#xD;
      these treatments often require long hospitalization, highly skilled operators, without&#xD;
      certain results and with high rates of complications.&#xD;
&#xD;
      The aim of this study is to exploit the regenerative-tissue capacities of autologous&#xD;
      emulsified adipose tissue-derived stromal vascular fraction (tSVFem, widely used in other&#xD;
      medical fields - like plastic surgery -for different purposes) harvested and delivered&#xD;
      locally by endoscopy to close the GI fistula. Indeed, the anti-inflammatory and&#xD;
      regenerative-tissue promoting effects of tSVFem may safely promote rapid and effective tissue&#xD;
      healing as alternative, and in this setting they were not investigated before. Fistulas are&#xD;
      often long-standing chronic conditions, thus healing mechanisms are delayed and subverted in&#xD;
      favor of inflammation and fibrosis, resembling chronic inflammatory diseases. Delivery of&#xD;
      tSVFem is a promising new approach that promotes healing in virtue of its immunosuppressive,&#xD;
      immunomodulatory, pro-angiogenic and regenerative potentials. Since the grafted material used&#xD;
      in this study is autologous, there is no risk for rejection. All the procedures are performed&#xD;
      under general anesthesia with orotracheal intubation or laryngeal mask. Approximately 30 cc&#xD;
      of fat are harvested from the superficial layer of subcutaneous tissue by a 2.1 mm&#xD;
      microcannula with 4, 1-mm size holes, arranged in a single raw, to get the so-called&#xD;
      &quot;microfat&quot;. Twenty cc of the harvested microfat are mechanical emulsified by sequential&#xD;
      passages through 2.4mm and 1.2mm filters, and a 600/400 μm disposable filtering device.&#xD;
&#xD;
      Then the material is centrifuged at 3000 rounds for three minutes, obtaining the tSVFem after&#xD;
      removal of supernatant fraction and oil released upon mature adipocytes mechanical&#xD;
      disruption.&#xD;
&#xD;
      Subsequently, an endoscopy is performed to inject 10 cc of microfat into the fistula (through&#xD;
      a 6-French catheter) until it was completely filled. Then, with a 22 Gauge endoscopic needle,&#xD;
      a total of 1-2 cc of tSVFem were injected into the submucosa of the 4 quadrants of the&#xD;
      fistula borders, to obliterate it completely.&#xD;
&#xD;
      A radiologic and endoscopic control at day-7 is done to evaluate complete healing of the&#xD;
      fistula.&#xD;
&#xD;
      The technique proposed by the investigators for the treatment of GI fistulas with tSVFem&#xD;
      requires a minimal, inexpensive, easily reproducible mechanical manipulation of autologous&#xD;
      adipose tissue without necessity of any enzymatic digestion or cell expansion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">April 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fistula healing</measure>
    <time_frame>7 days after the injection procedure of tSVFem</time_frame>
    <description>Rate of healing of fistula at endoscopy and gastrografin swallow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment adverse events and complications</measure>
    <time_frame>During the procedure, 7 days after and at 1-2 month follow-up</time_frame>
    <description>To evaluate the percentage of patients that developed adverse events or any complications during and after the treatment proposed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastrointestinal Fistula</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated by endoscopic injection of emulsified adipose tissue stromal vascular fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>injection of emulsified adipose tissue stromal vascular fraction</intervention_name>
    <description>Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        • Patients affected by GI fistulas, not fit for surgical treatments of after failure of&#xD;
        conventional conservative treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enteroenteric fistulas&#xD;
&#xD;
          -  Patients who do not sign informed consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Venanzio Porziella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario A. Gemelli, IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dania Nachira, MD</last_name>
    <phone>00390630155692</phone>
    <email>dania.nachira@policlinicogemelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dania Nachira</last_name>
    <phone>00390630155692</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione Policlinico Agostino Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Venanzio Porziella</last_name>
      <phone>00390630156353</phone>
      <email>Venanzio.porziella@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Venanzio Porziella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dania Nachira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivo Boskoski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelo Trivisonno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Brinster CJ, Singhal S, Lee L, Marshall MB, Kaiser LR, Kucharczuk JC. Evolving options in the management of esophageal perforation. Ann Thorac Surg. 2004 Apr;77(4):1475-83. Review.</citation>
    <PMID>15063302</PMID>
  </reference>
  <reference>
    <citation>Porziella V, Nachira D, Boškoski I, Trivisonno A, Costamagna G, Margaritora S. Emulsified stromal vascular fraction tissue grafting: a new frontier in the treatment of esophageal fistulas. Gastrointest Endosc. 2020 Dec;92(6):1262-1263. doi: 10.1016/j.gie.2020.06.019. Epub 2020 Jul 4.</citation>
    <PMID>32634381</PMID>
  </reference>
  <reference>
    <citation>Kuehn F, Loske G, Schiffmann L, Gock M, Klar E. Endoscopic vacuum therapy for various defects of the upper gastrointestinal tract. Surg Endosc. 2017 Sep;31(9):3449-3458. doi: 10.1007/s00464-016-5404-x. Epub 2017 Jan 11. Review.</citation>
    <PMID>28078463</PMID>
  </reference>
  <reference>
    <citation>Brangewitz M, Voigtländer T, Helfritz FA, Lankisch TO, Winkler M, Klempnauer J, Manns MP, Schneider AS, Wedemeyer J. Endoscopic closure of esophageal intrathoracic leaks: stent versus endoscopic vacuum-assisted closure, a retrospective analysis. Endoscopy. 2013 Jun;45(6):433-8. doi: 10.1055/s-0032-1326435. Epub 2013 Jun 3.</citation>
    <PMID>23733727</PMID>
  </reference>
  <reference>
    <citation>Ceccarelli S, Pontecorvi P, Anastasiadou E, Napoli C, Marchese C. Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application. Front Cell Dev Biol. 2020 Apr 17;8:236. doi: 10.3389/fcell.2020.00236. eCollection 2020. Review.</citation>
    <PMID>32363193</PMID>
  </reference>
  <reference>
    <citation>Angelo Trivisonno, Marc Abecassis, Massimo Monti et al. Adipose Tissue: From Energy Reservoir to a Source of Cells for Epithelial Tissue Engineering. In: Stem Cells in Aesthetic Procedures: Springer Berlin Heidelberg,2014:303-326</citation>
  </reference>
  <reference>
    <citation>Trivisonno A, Nachira D, Boškoski I, Calcagni F, Tringali A, Costamagna G, Margaritora S, Porziella V. Autologous Fat Grafting Restores Soft-tissue Contour Deformities after Vascular Anomaly: Widening the Horizons of Employment of Autologous Fat Grafting. Plast Reconstr Surg Glob Open. 2019 Nov 27;7(11):e2518. doi: 10.1097/GOX.0000000000002518. eCollection 2019 Nov.</citation>
    <PMID>31942308</PMID>
  </reference>
  <reference>
    <citation>Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016 Sep 24;388(10051):1281-90. doi: 10.1016/S0140-6736(16)31203-X. Epub 2016 Jul 29.</citation>
    <PMID>27477896</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</investigator_affiliation>
    <investigator_full_name>Venanzio Porziella</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>gastrointestinal fistula</keyword>
  <keyword>Adipose-derived stem cells</keyword>
  <keyword>adipose tissue stromal vascular fraction</keyword>
  <keyword>Endoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

